Every year, thousands of patients sit in doctors’ offices with needles in their arms receiving a dose of a wonder drug called Keytruda. The cancer medicine is one of the world’s best sellers, earning Merck $29.5bn in sales last year. But drip by drip, the US pharmaceutical company’s time is running out.
每年，成千上萬的患者坐在醫生辦公室，手臂上插著針，接受一種名為可瑞達(Keytruda)的神奇藥物治療。這款癌癥藥物是全球最暢銷的藥物之一，去年為默克(Merck)帶來了295億美元的銷售額。但隨著一滴滴藥液注入，默克的專利保護期也在逐漸流逝。
您已閱讀2%（426字），剩余98%（21180字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。